Sygnis SA

Equities

SYG

PLMODE000019

Biotechnology & Medical Research

End-of-day quote Warsaw S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
0.614 ^PLN	-0.65%		-1.60%	-31.47%

May. 15	Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 14	Sygnis SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2022

May 13, 2022 at 02:14 pm EDT

Sygnis SA reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was PLN 0.961959 million. Revenue was PLN 12.73 million compared to PLN 0.894399 million a year ago. Net income was PLN 3.43 million compared to PLN 0.075791 million a year ago.

Latest news about Sygnis SA

Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Sygnis SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14	CI
Sygnis SA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Sygnis SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Sygnis SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Sygnis SA Auditor Raises 'Going Concern' Doubt	23-03-19	CI
Sygnis SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Sygnis SA acquired majority stake in ZMorph sp. z o.o. from Warsaw Equity Group for PLN 3.64 Million.	22-07-28	CI
Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Sygnis SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
Sygnis SA Auditor Raises 'Going Concern' Doubt	22-03-20	CI
MODE S.A. will Change its Name to Sygnis SA	22-01-28	CI
MODE S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
MODE S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-12	CI
Mode S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
An unknown buyer acquired 14.92% stake in MODE S.A. from SETANTA Alternatywna Spólka Inwestycyjna Spólka Akcyjna.	18-06-17	CI

Chart Sygnis SA

Duration

Period

More charts

Company Profile

Sygnis SA is a Poland-based company, which egages in Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SYGNIS SA	-31.47%	3.93M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.40%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research